AEterna Zentaris Inc. (Nasdaq: AEZS) reported disappointing Phase 3 results for its prostate and urinary disease drug treatement. The stock skidded $1.70 to $1.13.
Disappointing Trial Results For AEterna Zentaris
August 17, 2009 at 13:56 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.